A Single-Arm, Multicenter, Phase II Clinical Trial of CS1001 in Subjects With Relapsed or Refractory Classical Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs CS 1001 (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors CStone Pharmaceuticals
- 17 Dec 2018 Planned number of patients changed from 68 to 80.
- 16 Jul 2018 Status changed from not yet recruiting to recruiting.
- 13 Jun 2018 According to a CStone media release, first patient has been dosed in this trial.